Health & Biotech
ASX Health Stocks: GTG pivots to US, vows to build a more efficient business
Althea seals joint venture to enter lucrative US cannabis beverages market
‘Huge economic potential’ – Moves to make Australia shine as a medical manufacturer
PharmAust raises $7.8 million in hot SPP
Orthocell ramps up global expansion of market-leading regenerative medicine products
ASX Health Stocks: Alcidion soars as it helps bring UK patient records into digital age
LTR Pharma raises $10.5m to advance erectile dysfunction treatment SPONTAN
EZZ reports strong Q4 with customer receipts up 70pc to $23 million
Australia’s medical manufacturing sector – a global success story in the making
ASX Health Stocks: Focus on retina-disease drug study draws eyes
Dr Boreham’s Crucible: Sleep diagnostics stayer is still dreaming big
ASX Health Stocks: Immutep gets positive FDA feedback for lung cancer therapy
ScoPo’s Powerplays: ASX health stocks rise amid renewed positive sentiment
Imricor Medical Systems raising $35m to fund growth strategy
ASX Health Stocks: Neuren’s treatment for cruel kids’ disease on fast track
Beyond Resources Part 2: ASX companies driving WA’s medical and life sciences sector
Neurotech Phase 2/3 autism trial shows uplift in mood while lowering anxiety and depression
Featured Health & Biotech Stocks
Health & Biotech
Healthcare stocks are as varied as the solutions they are working to solve. The sector covers biotech stocks developing breakthrough pharmaceutical drugs and vaccines to medtech companies launching the latest and greatest medical devices they hope will change the face of healthcare.
Even the ‘budding’ medical cannabis industry is in the mix as researchers explore new applications and treatments.
If you want to know what’s happening with emerging health stocks on the ASX, Stockhead has you covered, with daily stock news, expert insight and research. You can also recap broader industry trends and recent share price movements across the sector in our regular ‘Check Up’ feature.
Accurate, up-to-date news stories are important, especially in the health sector where progress is often slow and risk often high. That’s why we’re focused on helping small cap investors make sense of the medical jargon.
